Business
Pharmaceuticals: Schering-Plough, Roche will market new medicines for hepatitis.
Aug. 14, 2001
IDEC Pharmaceuticals Corp. of La Jolla and Mountain View has appointed Clifford Orent as general counsel and vice president for corporate development, effective Feb. 13.
Jan. 5, 1989
Capping years of regulatory clashes with one of Orange County’s most flamboyant corporate executives, the U.S.
Aug. 12, 1999
Big Pharma bulks up with Merck-Schering deal
March 10, 2009
Wall Street is buoyed by the $33-billion buyout deal of HCA and strong earnings reports from drug makers Merck and Schering-Plough.
July 25, 2006
Politics
In the last three years, the drug company Schering-Plough has spent more than $12 million lobbying Congress to pass legislation extending its exclusive rights to the blockbuster antihistamine Claritin, which will otherwise expire in 2002.
Nov. 9, 1999
Shareholders of Los Angeles-based Cal Fed Bancorp Inc., the parent company of California Federal Bank, approved its $1.2-billion merger with First Nationwide Holdings Inc., the parent of First Nationwide Bank. . . .
Dec. 17, 1996
ICN Pharmaceuticals Inc. agreed to license as many as three hepatitis-fighting compounds to Schering-Plough Corp. to settle a research dispute, ICN said in a document filed Tuesday with the U.S.
Nov. 15, 2000
The New Jersey firm will market German maker’s primary care drugs in U.S.
Sept. 14, 2004
Revenue from Organon Biosciences would increase the firm’s sales by half. But the deal’s debt raises concerns.
March 13, 2007